Results 151 to 160 of about 6,222 (193)

Characterizing mouse platelet heterogeneity across diverse disease models using spectral flow cytometry and high-dimensional analysis. [PDF]

Res Pract Thromb Haemost
Gautam D, Clarke EM, Zon RL, Smith-Oliver MR, Kumar A, Sullivan ME, Karagiannis P, Roweth HG, Battinelli EM.   +8 more
europepmc   +1 more source

rFVIIIa-platelet binding enhances platelet procoagulant activity independently of thrombin generation. [PDF]

Blood Vessel Thromb Hemost
Strebel A, Lickert S, Klamroth R, Vogel V, Pennacchio FA.   +4 more
europepmc   +1 more source

Interferon receptor gene dosage differentially regulates hypoxia-induced platelet activation and pulmonary hypertension in down syndrome. [PDF]

Front Immunol
Posey JN, Jordan M, Olsen-Dufour A, Nguyen TN, Farrell C, Lewis CV, Archambault JL, Sul C, Colon-Hidalgo D, Nozik ES, Espinosa JM, Sullivan KD, Delaney C.   +12 more
europepmc   +1 more source

Biomarkers of Cardioembolic Stroke in Thrombus Composition: Diagnostic Value of DNA and Fibrin Content. [PDF]

Eur J Neurol
Fasille J, Nomenjanahary MS, Faille D, Habay C, Bedoucha L, Kyheng M, Labreuche J, Consoli A, Lapergue B, Piotin M, Blanc R, Ho-Tin-Noé B, Mazighi M, Desilles JP, Di Meglio L, Compo CLOT Study Group.   +15 more
europepmc   +1 more source

Receptor homodimerisation significantly prolongs the lifetime of ligand-induced crosslinking of CLEC-2 but not GPVI

Clark J, Martin E, Slater A, Calebiro D, Koszegi Z, Watson S.   +5 more
europepmc   +1 more source

Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis

May CJ, Trory JS, Webb CE, Walker HS, Li Y, Poole AW, Vautrinot J, Tromans J, Hers I.   +8 more
europepmc   +1 more source

A Comparative Assessment Study of Known Small-molecule GPVI Modulators

ACS Medicinal Chemistry Letters, 2022
The GPVI platelet receptor was recently validated as a safe antiplatelet target for the treatment of thrombosis using several peptidic modulators. In contrast, few weakly potent small-molecule GPVI antagonists have been reported.
Mark J Howard, Julia S Gauer, Clare Wilson   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction

Thrombosis and Haemostasis, 2009
SummaryThe Extracellular Matrix Metalloproteinase Inducer (EMMPRIN, CD147, basigin) is an immunoglobulin-like receptor expressed in various cell types. During cellular interactions homotypic EMMPRIN-EMMPRIN interactions are known to induce the synthesis of matrix metalloproteinases. Recently, we have identified EMMPRIN as a novel receptor on platelets.
Konstantinos Stellos, Dietmar Vestweber
exaly   +3 more sources

Presence of platelet-associated anti-glycoprotein (GP)VI autoantibodies and restoration of GPVI expression in patients with GPVI deficiency [PDF]

Journal of Thrombosis and Haemostasis, 2009
Glycoprotein (GP)VI deficiency is a rare platelet disorder with a mild bleeding tendency. However, its pathophysiology remains unclear.We characterized a novel GPVI-deficient patient with immune thrombocytopenic purpura and searched for the presence of anti-GPVI autoantibodies in this and another patient with GPVI deficiency.A 12-year-old Japanese girl
Hirokazu Kashiwagi, Y Tomiyama, M Moroi
exaly   +4 more sources

GPVI and CLEC-2 in hemostasis and vascular integrity [PDF]

Journal of Thrombosis and Haemostasis, 2010
The glycoprotein VI (GPVI)-FcR gamma-chain complex initiates powerful activation of platelets by the subendothelial matrix proteins collagen and laminin through an immunoreceptor tyrosine-based activation motif (ITAM)-regulated signaling pathway. ITAMs are characterized by two YxxL sequences separated by 6-12 amino acids and are found associated with ...
Steve P. Watson
exaly   +3 more sources